Novartis Acquires Chinook Therapeutics for $3.5 Billion, Enhancing Late-Stage Pipeline

Leading pharmaceutical company Novartis recently announced a deal to purchase Seattle-based biotech company Chinook Therapeutics for up to $3.5 billion. By introducing cutting-edge therapy for rare and serious kidney diseases, Novartis hopes to strengthen its late-stage drug development portfolio. In the second half of 2023, the merger between a former Novartis subsidiary and Chinook is anticipated to be finalized.

Novartis Acquires Chinook Therapeutics for $3.5 Billion

Section 1: Novartis' Acquisition of Chinook Therapeutics

Novartis (NOVN.S) has made a significant investment in the biotech industry by agreeing to get Chinook Therapeutics (KDNY.O) for up to $3.5 billion. The Swiss drugmaker aims to expand its late-stage drug development pipeline by pursuing a groundbreaking treatment for rare kidney disease.

Section 2: Transaction Details and Closing Timeline

The merger between Novartis and Chinook will take the form of a formed Novartis subsidiary. The transaction is projected to conclude in the second half of 2023, as stated by Novartis in an official statement. As per the agreed terms, Chinook shareholders will receive $3.2 billion in cash, equal to $40 per share. Also, they will be entitled to a contingent value right valued at up to $300 million, based on specific regulatory accomplishments.

Section 3: Evaluation of Chinook Therapeutics

Chinook Therapeutics, headquartered in Seattle, is engaged in biotech research and development. The company has shown promising progress in its clinical trials for a novel oral drug candidate called atrasentan. This candidate targets IgA nephropathy (IgAN), a kidney disease characterized by its severity. The pivotal readout of a clinical trial in the third and final stage of atrasentan's development is anticipated to be announced in the fourth quarter of this year.

Section 4: Future Prospects and Expansion Plans

Chinook Therapeutics is concentrating on developing zigakibart, another experimental treatment for IgAN, and also atrasentan. The company plans to begin or start a Phase 3 clinical trial for zigakibart in the third quarter of 2023. This proactive approach demonstrates Chinook's dedication to creating cutting-edge treatments and increasing its range of therapeutic options for patients with this crippling kidney condition.


Novartis' acquisition of Chinook Therapeutics for $3.5 billion represents a significant step in augmenting its late-stage drug development portfolio. By incorporating Chinook's potential therapies for severe kidney diseases, Novartis aims to address critical unmet medical needs. This strategic move showcases Novartis' commitment to advancing healthcare and improving the lives of patients worldwide.

Post a Comment

Previous Post Next Post